Advertisement
Mr. KAM Yuen, Chairman and CEO of Golden Meditech, said that despite theglobal financial crisis has caused extreme volatility in the capital marketthat resulted in numerous companies' fundamentals being casually ignored,Golden Meditech has demonstrated its ability to bring in new financialinvestor. It represents a vote of confidence from the investment communityand a conviction of Golden Meditech strong fundamentals and promising outlookwhich was temporarily overshadowed by the pessimism in the capital market.
Advertisement
"We are honored to see that Atlantis Investment shares the same vision aswe do with China's burgeoning healthcare industry and such a strategicinvestor-ship will not only strengthen Golden Meditech shareholders base, butalso be beneficial to our long-term growth," said Mr. KAM.
"To act in the best interest of our shareholders, Golden Meditech hasalways been striving to maximize shareholders value. While enhancing theshareholder value, we also engage in various defensive measures, includingshare repurchases, for the purpose of preserving shareholder value," said Mr.KAM.
The net proceeds raised will be used for general working capital, and tofund future investment opportunities.
As of September 20, 2008, Golden Meditech reported sustained high growthof key businesses and recorded revenues of HK$241 million in the first half offinancial year 2008/09, representing a 27% growth on a year on year basis.Net profit attributable to shareholders of the same period was HK$147 million.
Golden Meditech: Founded in 2000 and listed on the Growth EnterpriseMarket of the Stock Exchange of Hong Kong Limited in December 2001, GoldenMeditech is the first hi-tech medical device enterprise that went publicoutside of the PRC. During the past few years, thanks to its great efforts ininnovation and market expansion, as well as its first-mover abilities incapturing the emerging market opportunities, Golden Meditech's medical devices,cord blood banking services and natural herbal medicines have all establisheddominant positions in their own sectors. Going forward, Golden Meditech willcontinue its pursuit of becoming China's leading integrated medical groupthrough organic growth, acquisitions and strategic investments.
Atlantis Investment Management Limited: an independent Asian equity assetmanagement firm with over US$4.5bn under management as at January 31, 2008,with a focus on China and the Asia-Pacific countries.For inquiries, please kindly contact: Investor Relations Division Golden Meditech Company Limited Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong. Tel: +852-3605-8138 Fax: +852-3605-8181 Email: [email protected]
SOURCE Golden Meditech Company Limited
